| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemangioma, Cavernous, Central Nervous System | 83 | 2025 | 257 | 21.560 |
Why?
|
| Cerebral Hemorrhage | 94 | 2025 | 362 | 14.700 |
Why?
|
| Tissue Plasminogen Activator | 31 | 2025 | 180 | 4.620 |
Why?
|
| Intracranial Arteriovenous Malformations | 49 | 2024 | 121 | 4.460 |
Why?
|
| Brain Neoplasms | 35 | 2022 | 810 | 4.250 |
Why?
|
| Fibrinolytic Agents | 29 | 2025 | 238 | 4.230 |
Why?
|
| Thrombolytic Therapy | 20 | 2025 | 253 | 3.590 |
Why?
|
| Hemangioma, Cavernous | 24 | 2021 | 66 | 3.420 |
Why?
|
| Magnetic Resonance Imaging | 71 | 2025 | 3450 | 2.640 |
Why?
|
| Minimally Invasive Surgical Procedures | 21 | 2025 | 282 | 2.580 |
Why?
|
| Intracranial Hemorrhages | 16 | 2024 | 135 | 2.360 |
Why?
|
| Neurosurgical Procedures | 18 | 2025 | 350 | 1.950 |
Why?
|
| Intracranial Aneurysm | 28 | 2012 | 201 | 1.940 |
Why?
|
| Humans | 318 | 2025 | 93138 | 1.900 |
Why?
|
| rho-Associated Kinases | 13 | 2025 | 161 | 1.830 |
Why?
|
| Capillary Permeability | 6 | 2021 | 131 | 1.810 |
Why?
|
| Cerebral Ventricles | 11 | 2018 | 65 | 1.790 |
Why?
|
| Biomarkers | 20 | 2025 | 1905 | 1.720 |
Why?
|
| Apoptosis Regulatory Proteins | 17 | 2023 | 201 | 1.690 |
Why?
|
| Disease Models, Animal | 21 | 2024 | 2479 | 1.610 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2023 | 663 | 1.580 |
Why?
|
| Male | 171 | 2025 | 44357 | 1.570 |
Why?
|
| Hematoma | 13 | 2024 | 105 | 1.570 |
Why?
|
| Hemorrhage | 10 | 2023 | 289 | 1.540 |
Why?
|
| Drainage | 13 | 2022 | 170 | 1.500 |
Why?
|
| Central Nervous System Vascular Malformations | 8 | 2023 | 40 | 1.490 |
Why?
|
| Female | 175 | 2025 | 48544 | 1.470 |
Why?
|
| Stroke | 20 | 2024 | 1073 | 1.450 |
Why?
|
| Brain | 40 | 2021 | 2337 | 1.420 |
Why?
|
| Middle Aged | 129 | 2025 | 27540 | 1.420 |
Why?
|
| Central Nervous System Neoplasms | 6 | 2019 | 98 | 1.400 |
Why?
|
| Adult | 119 | 2025 | 27850 | 1.300 |
Why?
|
| KRIT1 Protein | 23 | 2023 | 61 | 1.270 |
Why?
|
| Epilepsy | 16 | 2020 | 434 | 1.190 |
Why?
|
| Treatment Outcome | 54 | 2025 | 9074 | 1.180 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 6 | 2024 | 10 | 1.100 |
Why?
|
| Microtubule-Associated Proteins | 14 | 2022 | 184 | 1.060 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 6 | 2020 | 36 | 1.050 |
Why?
|
| Aged | 87 | 2025 | 20399 | 1.030 |
Why?
|
| Neurosurgery | 10 | 2011 | 140 | 1.030 |
Why?
|
| Young Adult | 27 | 2025 | 6922 | 1.000 |
Why?
|
| Carotid Artery Diseases | 12 | 2011 | 100 | 0.990 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2024 | 391 | 0.990 |
Why?
|
| Clinical Trials as Topic | 9 | 2023 | 1098 | 0.940 |
Why?
|
| Intensive Care Units | 3 | 2023 | 450 | 0.930 |
Why?
|
| Machine Learning | 4 | 2025 | 346 | 0.890 |
Why?
|
| Subarachnoid Hemorrhage | 12 | 2018 | 152 | 0.880 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2025 | 393 | 0.880 |
Why?
|
| Prospective Studies | 18 | 2025 | 4546 | 0.860 |
Why?
|
| Sirolimus | 3 | 2024 | 176 | 0.850 |
Why?
|
| Cerebrovascular Disorders | 12 | 2004 | 138 | 0.840 |
Why?
|
| Propranolol | 2 | 2022 | 42 | 0.840 |
Why?
|
| Adolescent | 50 | 2025 | 9550 | 0.840 |
Why?
|
| Iron | 5 | 2018 | 173 | 0.800 |
Why?
|
| Brain Ischemia | 16 | 2023 | 407 | 0.780 |
Why?
|
| B-Lymphocytes | 5 | 2018 | 703 | 0.770 |
Why?
|
| Endothelial Cells | 17 | 2024 | 477 | 0.770 |
Why?
|
| MicroRNAs | 2 | 2025 | 581 | 0.760 |
Why?
|
| Laser Therapy | 2 | 2021 | 150 | 0.760 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2019 | 392 | 0.750 |
Why?
|
| Tomography, X-Ray Computed | 41 | 2025 | 2562 | 0.740 |
Why?
|
| Cerebral Angiography | 29 | 2017 | 213 | 0.730 |
Why?
|
| Mutation | 17 | 2024 | 4265 | 0.730 |
Why?
|
| Membrane Proteins | 8 | 2021 | 1260 | 0.730 |
Why?
|
| Neovascularization, Pathologic | 9 | 2024 | 353 | 0.720 |
Why?
|
| Carotid Artery, Internal | 11 | 2011 | 69 | 0.700 |
Why?
|
| Catheterization | 6 | 2012 | 217 | 0.690 |
Why?
|
| Mice | 28 | 2024 | 12224 | 0.690 |
Why?
|
| Craniotomy | 6 | 2021 | 88 | 0.680 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2021 | 7 | 0.670 |
Why?
|
| Socioeconomic Factors | 2 | 2023 | 627 | 0.670 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2020 | 1269 | 0.660 |
Why?
|
| Animals | 43 | 2025 | 27965 | 0.630 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 3 | 2019 | 5 | 0.620 |
Why?
|
| Aneurysm, Ruptured | 5 | 2012 | 60 | 0.610 |
Why?
|
| Cohort Studies | 17 | 2025 | 3044 | 0.600 |
Why?
|
| Risk Assessment | 13 | 2024 | 2434 | 0.580 |
Why?
|
| Root Cause Analysis | 1 | 2018 | 3 | 0.580 |
Why?
|
| Arteriovenous Malformations | 6 | 2023 | 49 | 0.580 |
Why?
|
| Cerebrovascular Circulation | 8 | 2021 | 229 | 0.550 |
Why?
|
| Seizures | 8 | 2020 | 312 | 0.550 |
Why?
|
| Child | 33 | 2020 | 7273 | 0.540 |
Why?
|
| Thrombophilia | 1 | 2017 | 22 | 0.530 |
Why?
|
| Zebrafish Proteins | 4 | 2024 | 159 | 0.530 |
Why?
|
| Endothelium, Vascular | 12 | 2020 | 436 | 0.520 |
Why?
|
| Postoperative Complications | 17 | 2012 | 2552 | 0.510 |
Why?
|
| Simvastatin | 2 | 2019 | 106 | 0.510 |
Why?
|
| Transcriptome | 6 | 2024 | 762 | 0.510 |
Why?
|
| Risk Factors | 24 | 2025 | 5901 | 0.510 |
Why?
|
| Embolization, Therapeutic | 9 | 2011 | 272 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 603 | 0.500 |
Why?
|
| Thromboembolism | 1 | 2017 | 122 | 0.500 |
Why?
|
| X-Ray Microtomography | 2 | 2019 | 102 | 0.500 |
Why?
|
| Cytokines | 2 | 2017 | 862 | 0.490 |
Why?
|
| Critical Care | 5 | 2013 | 442 | 0.490 |
Why?
|
| Double-Blind Method | 10 | 2025 | 1727 | 0.490 |
Why?
|
| Carrier Proteins | 9 | 2019 | 660 | 0.470 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2024 | 76 | 0.470 |
Why?
|
| Cerebral Veins | 9 | 2021 | 29 | 0.460 |
Why?
|
| Child, Preschool | 17 | 2020 | 3781 | 0.460 |
Why?
|
| Stereotaxic Techniques | 8 | 2024 | 81 | 0.460 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 7039 | 0.450 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 173 | 0.450 |
Why?
|
| Brain Mapping | 11 | 2016 | 565 | 0.440 |
Why?
|
| Cerebral Small Vessel Diseases | 3 | 2024 | 9 | 0.440 |
Why?
|
| Prognosis | 20 | 2023 | 3891 | 0.430 |
Why?
|
| Follow-Up Studies | 23 | 2023 | 3815 | 0.420 |
Why?
|
| Reproducibility of Results | 13 | 2025 | 2705 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2024 | 2465 | 0.410 |
Why?
|
| Temporal Lobe | 15 | 2003 | 187 | 0.410 |
Why?
|
| Antigen-Antibody Complex | 1 | 2014 | 88 | 0.410 |
Why?
|
| Vitamin D | 1 | 2016 | 272 | 0.400 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 638 | 0.400 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 1578 | 0.390 |
Why?
|
| Signal Transduction | 12 | 2024 | 3497 | 0.390 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 1719 | 0.390 |
Why?
|
| Zebrafish | 4 | 2024 | 339 | 0.380 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2023 | 297 | 0.380 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 504 | 0.380 |
Why?
|
| Hypertension | 3 | 2022 | 748 | 0.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2021 | 165 | 0.370 |
Why?
|
| Time Factors | 13 | 2025 | 5379 | 0.360 |
Why?
|
| Mechanical Thrombolysis | 1 | 2012 | 18 | 0.360 |
Why?
|
| Hemangioma | 6 | 1994 | 62 | 0.360 |
Why?
|
| Intracranial Pressure | 9 | 2020 | 75 | 0.360 |
Why?
|
| Hydrocephalus | 3 | 2022 | 78 | 0.360 |
Why?
|
| Mice, Knockout | 9 | 2024 | 2121 | 0.360 |
Why?
|
| Kruppel-Like Transcription Factors | 7 | 2024 | 109 | 0.350 |
Why?
|
| Cerebral Cortex | 9 | 2020 | 567 | 0.350 |
Why?
|
| Postoperative Care | 1 | 2013 | 232 | 0.350 |
Why?
|
| Vascular Surgical Procedures | 4 | 2020 | 151 | 0.350 |
Why?
|
| Aneurysm | 1 | 2011 | 57 | 0.340 |
Why?
|
| Observer Variation | 6 | 2016 | 570 | 0.340 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 163 | 0.340 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 6 | 2023 | 15 | 0.340 |
Why?
|
| Gene Expression | 5 | 2004 | 1304 | 0.340 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2004 | 76 | 0.340 |
Why?
|
| Choroid Plexus | 1 | 2011 | 16 | 0.340 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 1704 | 0.340 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 132 | 0.330 |
Why?
|
| Knowledge | 2 | 2009 | 30 | 0.330 |
Why?
|
| Leukocytes | 4 | 2021 | 210 | 0.330 |
Why?
|
| Disease Progression | 8 | 2021 | 1529 | 0.330 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 144 | 0.330 |
Why?
|
| Cavernous Sinus | 6 | 2001 | 15 | 0.320 |
Why?
|
| Electroencephalography | 12 | 1999 | 798 | 0.320 |
Why?
|
| Retrospective Studies | 21 | 2024 | 10132 | 0.310 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 1160 | 0.310 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2008 | 242 | 0.310 |
Why?
|
| Catheters | 3 | 2023 | 96 | 0.310 |
Why?
|
| Pilot Projects | 3 | 2025 | 913 | 0.310 |
Why?
|
| Radiotherapy | 1 | 2012 | 319 | 0.310 |
Why?
|
| Biomedical Research | 2 | 2019 | 432 | 0.300 |
Why?
|
| Intracranial Hypertension | 3 | 2019 | 55 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 1998 | 80 | 0.290 |
Why?
|
| Brain Diseases | 7 | 2001 | 172 | 0.290 |
Why?
|
| Chemistry | 1 | 2008 | 46 | 0.290 |
Why?
|
| Biological Science Disciplines | 1 | 2008 | 13 | 0.290 |
Why?
|
| Nobel Prize | 1 | 2008 | 10 | 0.290 |
Why?
|
| Science | 1 | 2009 | 36 | 0.290 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2023 | 32 | 0.290 |
Why?
|
| Cerebral Revascularization | 7 | 2008 | 27 | 0.290 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 1910 | 0.290 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 2008 | 232 | 0.290 |
Why?
|
| Plasma Cells | 3 | 2020 | 84 | 0.280 |
Why?
|
| Ischemic Attack, Transient | 9 | 2003 | 184 | 0.280 |
Why?
|
| Intracranial Arteriosclerosis | 4 | 2023 | 63 | 0.270 |
Why?
|
| Cerebral Arteries | 10 | 2009 | 72 | 0.270 |
Why?
|
| Oligoclonal Bands | 1 | 2007 | 3 | 0.270 |
Why?
|
| Brain Stem | 4 | 2021 | 163 | 0.270 |
Why?
|
| Ventriculostomy | 3 | 2018 | 22 | 0.270 |
Why?
|
| Magnetic Resonance Spectroscopy | 6 | 2019 | 269 | 0.270 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 308 | 0.270 |
Why?
|
| Recovery of Function | 4 | 2025 | 340 | 0.260 |
Why?
|
| Nervous System Diseases | 5 | 1992 | 164 | 0.260 |
Why?
|
| Image Enhancement | 1 | 2010 | 498 | 0.260 |
Why?
|
| Quality of Life | 3 | 2025 | 1776 | 0.260 |
Why?
|
| Tissue Scaffolds | 1 | 2008 | 128 | 0.260 |
Why?
|
| Phenotype | 10 | 2024 | 2545 | 0.260 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 435 | 0.260 |
Why?
|
| Surgical Instruments | 3 | 2011 | 61 | 0.260 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2002 | 47 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2020 | 916 | 0.250 |
Why?
|
| Neurologic Examination | 7 | 2005 | 118 | 0.250 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 63 | 0.250 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 465 | 0.250 |
Why?
|
| Muscle Proteins | 3 | 2021 | 129 | 0.250 |
Why?
|
| Neoplasms | 3 | 2021 | 3169 | 0.240 |
Why?
|
| Monitoring, Physiologic | 5 | 2020 | 255 | 0.240 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 4 | 2021 | 13 | 0.240 |
Why?
|
| Functional Laterality | 2 | 2025 | 204 | 0.240 |
Why?
|
| Survivors | 3 | 2022 | 204 | 0.240 |
Why?
|
| Epilepsy, Temporal Lobe | 9 | 2020 | 142 | 0.240 |
Why?
|
| Acute Disease | 7 | 2020 | 838 | 0.240 |
Why?
|
| Carotid Arteries | 4 | 2000 | 130 | 0.230 |
Why?
|
| Genotype | 7 | 2021 | 1866 | 0.230 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 1517 | 0.230 |
Why?
|
| Sensitivity and Specificity | 10 | 2021 | 1910 | 0.230 |
Why?
|
| RNA, Messenger | 4 | 2021 | 2020 | 0.220 |
Why?
|
| Patient Selection | 4 | 2023 | 688 | 0.220 |
Why?
|
| Moyamoya Disease | 1 | 2025 | 21 | 0.220 |
Why?
|
| Contrast Media | 4 | 2021 | 986 | 0.220 |
Why?
|
| Coronary Artery Disease | 2 | 2007 | 371 | 0.220 |
Why?
|
| Pain | 2 | 2025 | 412 | 0.220 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2001 | 113 | 0.220 |
Why?
|
| Radiosurgery | 6 | 2009 | 319 | 0.220 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2024 | 7 | 0.220 |
Why?
|
| Receptors, Cell Surface | 3 | 2018 | 291 | 0.210 |
Why?
|
| Feasibility Studies | 3 | 2021 | 753 | 0.210 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2024 | 9 | 0.210 |
Why?
|
| Chemokine CX3CL1 | 1 | 2024 | 6 | 0.210 |
Why?
|
| Brain Edema | 3 | 2013 | 54 | 0.210 |
Why?
|
| Epilepsies, Partial | 4 | 1991 | 52 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2024 | 1004 | 0.210 |
Why?
|
| Spinal Cord | 2 | 1999 | 236 | 0.200 |
Why?
|
| Cerebral Ventriculitis | 1 | 2023 | 1 | 0.200 |
Why?
|
| Astrocytes | 2 | 2021 | 136 | 0.200 |
Why?
|
| Encephalitis | 2 | 2015 | 46 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 619 | 0.200 |
Why?
|
| Immunohistochemistry | 6 | 2009 | 1786 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2020 | 595 | 0.200 |
Why?
|
| Angiography | 3 | 2011 | 192 | 0.190 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2022 | 70 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 279 | 0.190 |
Why?
|
| Affect | 1 | 2025 | 397 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 159 | 0.190 |
Why?
|
| Postoperative Hemorrhage | 2 | 2016 | 48 | 0.190 |
Why?
|
| Radiation Injuries | 1 | 2024 | 156 | 0.190 |
Why?
|
| White Matter | 2 | 2020 | 96 | 0.190 |
Why?
|
| Cerebellum | 3 | 2018 | 247 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2001 | 156 | 0.190 |
Why?
|
| Apoptosis | 2 | 2019 | 1719 | 0.180 |
Why?
|
| Circulating MicroRNA | 1 | 2022 | 14 | 0.180 |
Why?
|
| Endarterectomy, Carotid | 2 | 2000 | 74 | 0.180 |
Why?
|
| Occipital Lobe | 2 | 1999 | 24 | 0.180 |
Why?
|
| Leukoaraiosis | 1 | 2021 | 3 | 0.180 |
Why?
|
| Fibrinolysis | 1 | 2022 | 35 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 381 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 626 | 0.170 |
Why?
|
| DNA Mutational Analysis | 6 | 2024 | 543 | 0.170 |
Why?
|
| Health Services | 1 | 2002 | 53 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2543 | 0.170 |
Why?
|
| Cell Culture Techniques | 2 | 2001 | 195 | 0.170 |
Why?
|
| Depression | 2 | 2025 | 540 | 0.170 |
Why?
|
| Electrodes | 2 | 1992 | 97 | 0.170 |
Why?
|
| Epoprostenol | 3 | 1989 | 46 | 0.170 |
Why?
|
| Motor Cortex | 3 | 2001 | 209 | 0.170 |
Why?
|
| Morbidity | 1 | 2021 | 162 | 0.170 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2021 | 24 | 0.170 |
Why?
|
| Patient Participation | 1 | 2023 | 229 | 0.170 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 52 | 0.170 |
Why?
|
| Microfilament Proteins | 3 | 2018 | 208 | 0.170 |
Why?
|
| Genetic Markers | 5 | 2005 | 469 | 0.160 |
Why?
|
| ADAMTS5 Protein | 1 | 2020 | 4 | 0.160 |
Why?
|
| Versicans | 1 | 2020 | 7 | 0.160 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2021 | 39 | 0.160 |
Why?
|
| Perfusion Imaging | 1 | 2021 | 48 | 0.160 |
Why?
|
| Vascular Diseases | 3 | 2017 | 117 | 0.160 |
Why?
|
| Research | 1 | 2002 | 250 | 0.160 |
Why?
|
| Mice, Mutant Strains | 3 | 2010 | 217 | 0.160 |
Why?
|
| Aging | 3 | 2020 | 725 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2019 | 91 | 0.160 |
Why?
|
| Plasminogen Activators | 1 | 2000 | 10 | 0.160 |
Why?
|
| Frontal Lobe | 3 | 2003 | 124 | 0.160 |
Why?
|
| Genes, Dominant | 3 | 2001 | 111 | 0.160 |
Why?
|
| Chronic Disease | 4 | 2020 | 941 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 453 | 0.160 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2000 | 49 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 555 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 7 | 2024 | 3430 | 0.160 |
Why?
|
| Bayes Theorem | 4 | 2022 | 403 | 0.150 |
Why?
|
| Neurotoxins | 1 | 2020 | 44 | 0.150 |
Why?
|
| Genetic Therapy | 2 | 2017 | 365 | 0.150 |
Why?
|
| Self Report | 1 | 2021 | 328 | 0.150 |
Why?
|
| Balloon Occlusion | 1 | 2000 | 28 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 2485 | 0.150 |
Why?
|
| Anticoagulants | 2 | 2024 | 455 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 56 | 0.150 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 555 | 0.150 |
Why?
|
| rhoA GTP-Binding Protein | 3 | 2020 | 87 | 0.150 |
Why?
|
| Head Injuries, Penetrating | 1 | 2020 | 67 | 0.150 |
Why?
|
| Cell Membrane Permeability | 2 | 2018 | 121 | 0.150 |
Why?
|
| Thrombectomy | 2 | 2023 | 220 | 0.150 |
Why?
|
| Abnormalities, Radiation-Induced | 1 | 1999 | 2 | 0.150 |
Why?
|
| Germinoma | 1 | 1999 | 3 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.150 |
Why?
|
| Infant | 8 | 2014 | 3156 | 0.150 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2020 | 53 | 0.150 |
Why?
|
| Thalamus | 3 | 2022 | 131 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 188 | 0.150 |
Why?
|
| Autoantigens | 1 | 2020 | 138 | 0.150 |
Why?
|
| Meningeal Neoplasms | 3 | 1990 | 69 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1926 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 200 | 0.140 |
Why?
|
| Age Factors | 6 | 2016 | 1896 | 0.140 |
Why?
|
| Thrombomodulin | 1 | 2018 | 9 | 0.140 |
Why?
|
| Protein C | 1 | 2018 | 7 | 0.140 |
Why?
|
| Neurosurgeons | 1 | 2019 | 45 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2020 | 276 | 0.140 |
Why?
|
| Visual Fields | 2 | 1998 | 100 | 0.140 |
Why?
|
| Pedigree | 7 | 2011 | 962 | 0.140 |
Why?
|
| Critical Pathways | 1 | 1999 | 36 | 0.140 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 61 | 0.140 |
Why?
|
| Intracranial Hypotension | 1 | 1998 | 4 | 0.140 |
Why?
|
| Cranial Fossa, Middle | 1 | 2018 | 12 | 0.140 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2018 | 23 | 0.140 |
Why?
|
| Vision Disorders | 2 | 1998 | 71 | 0.140 |
Why?
|
| Neurosciences | 1 | 2019 | 50 | 0.140 |
Why?
|
| Zinc | 1 | 2019 | 97 | 0.140 |
Why?
|
| Intraoperative Complications | 1 | 2000 | 191 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 3 | 1984 | 106 | 0.140 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 220 | 0.140 |
Why?
|
| Wounds, Gunshot | 1 | 2020 | 121 | 0.140 |
Why?
|
| Myosin Type II | 1 | 2018 | 50 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 458 | 0.140 |
Why?
|
| Amobarbital | 2 | 1995 | 7 | 0.140 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 334 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 328 | 0.140 |
Why?
|
| Memory Disorders | 3 | 1995 | 72 | 0.140 |
Why?
|
| Algorithms | 2 | 2008 | 1948 | 0.130 |
Why?
|
| Suction | 3 | 2013 | 38 | 0.130 |
Why?
|
| Thrombospondin 1 | 1 | 2017 | 22 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 196 | 0.130 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 1276 | 0.130 |
Why?
|
| Glioma | 3 | 1998 | 298 | 0.130 |
Why?
|
| Research Design | 3 | 2019 | 620 | 0.130 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2019 | 121 | 0.130 |
Why?
|
| Genetic Counseling | 3 | 2005 | 100 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 48 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2014 | 163 | 0.130 |
Why?
|
| Intestinal Mucosa | 2 | 2019 | 825 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 393 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2827 | 0.130 |
Why?
|
| Electrodes, Implanted | 4 | 1994 | 196 | 0.130 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 73 | 0.120 |
Why?
|
| Sodium Chloride | 1 | 2017 | 83 | 0.120 |
Why?
|
| Antigens, CD | 2 | 2014 | 476 | 0.120 |
Why?
|
| Corpus Callosum | 2 | 2003 | 56 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 885 | 0.120 |
Why?
|
| Permeability | 3 | 2021 | 143 | 0.120 |
Why?
|
| Histological Techniques | 1 | 2016 | 33 | 0.120 |
Why?
|
| Temporal Arteries | 2 | 2009 | 8 | 0.120 |
Why?
|
| Blood-Brain Barrier | 3 | 1994 | 79 | 0.120 |
Why?
|
| Circle of Willis | 1 | 1996 | 5 | 0.120 |
Why?
|
| Prevalence | 7 | 2023 | 1318 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2017 | 391 | 0.120 |
Why?
|
| Iodine | 1 | 2016 | 43 | 0.120 |
Why?
|
| Memory | 3 | 1995 | 225 | 0.120 |
Why?
|
| Blood Coagulation | 2 | 2018 | 90 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 576 | 0.120 |
Why?
|
| Somatosensory Cortex | 1 | 1997 | 109 | 0.120 |
Why?
|
| Neuroanatomy | 1 | 1995 | 3 | 0.120 |
Why?
|
| Point Mutation | 2 | 2009 | 237 | 0.120 |
Why?
|
| Endarterectomy | 3 | 1991 | 23 | 0.120 |
Why?
|
| Organ Size | 1 | 2016 | 360 | 0.110 |
Why?
|
| Demography | 1 | 2016 | 190 | 0.110 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 128 | 0.110 |
Why?
|
| Hospitalization | 1 | 2021 | 925 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 204 | 0.110 |
Why?
|
| Disability Evaluation | 3 | 2025 | 170 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 1996 | 348 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2001 | 1611 | 0.110 |
Why?
|
| Keratin-1 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Angioplasty | 2 | 2005 | 68 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2011 | 33 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 1998 | 87 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 889 | 0.110 |
Why?
|
| Stress Fibers | 1 | 2014 | 23 | 0.110 |
Why?
|
| Voice | 1 | 1994 | 18 | 0.110 |
Why?
|
| Laser Capture Microdissection | 1 | 2014 | 20 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 267 | 0.110 |
Why?
|
| American Heart Association | 3 | 2014 | 106 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 2009 | 0.100 |
Why?
|
| Visual Cortex | 1 | 1997 | 244 | 0.100 |
Why?
|
| Single-Chain Antibodies | 1 | 2014 | 21 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1732 | 0.100 |
Why?
|
| Logistic Models | 4 | 2021 | 1241 | 0.100 |
Why?
|
| Pseudotumor Cerebri | 1 | 1994 | 12 | 0.100 |
Why?
|
| Carotid Stenosis | 4 | 2005 | 113 | 0.100 |
Why?
|
| Chorea | 1 | 2014 | 14 | 0.100 |
Why?
|
| Survival Rate | 2 | 2009 | 1945 | 0.100 |
Why?
|
| History, 21st Century | 2 | 2019 | 187 | 0.100 |
Why?
|
| Music | 1 | 1994 | 35 | 0.100 |
Why?
|
| Subthalamic Nucleus | 1 | 2014 | 23 | 0.100 |
Why?
|
| Inflammation | 2 | 2011 | 1049 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 888 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2017 | 463 | 0.100 |
Why?
|
| Gadolinium | 1 | 2013 | 95 | 0.100 |
Why?
|
| History, 20th Century | 2 | 2019 | 312 | 0.100 |
Why?
|
| Prostaglandins | 2 | 1983 | 43 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2003 | 826 | 0.100 |
Why?
|
| Chicago | 1 | 2017 | 1452 | 0.100 |
Why?
|
| Women's Health | 1 | 2014 | 107 | 0.100 |
Why?
|
| Healthy Volunteers | 2 | 2025 | 148 | 0.090 |
Why?
|
| Gene Deletion | 3 | 2020 | 351 | 0.090 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2011 | 101 | 0.090 |
Why?
|
| Deep Brain Stimulation | 1 | 2014 | 89 | 0.090 |
Why?
|
| Decompression, Surgical | 2 | 2006 | 157 | 0.090 |
Why?
|
| Spinal Cord Compression | 2 | 2000 | 46 | 0.090 |
Why?
|
| Actins | 4 | 2005 | 467 | 0.090 |
Why?
|
| Intercellular Junctions | 2 | 2010 | 68 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1849 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 305 | 0.090 |
Why?
|
| Reference Values | 3 | 2002 | 603 | 0.090 |
Why?
|
| Stents | 3 | 2005 | 406 | 0.090 |
Why?
|
| Macrophages | 2 | 2021 | 609 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2004 | 57 | 0.090 |
Why?
|
| Vinblastine | 1 | 2012 | 84 | 0.090 |
Why?
|
| Bleomycin | 1 | 2012 | 99 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2025 | 336 | 0.090 |
Why?
|
| Jews | 1 | 2011 | 42 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2012 | 100 | 0.090 |
Why?
|
| Disease Management | 3 | 2020 | 357 | 0.090 |
Why?
|
| Dura Mater | 2 | 1996 | 44 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2025 | 655 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2014 | 618 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2011 | 97 | 0.080 |
Why?
|
| Incidence | 4 | 2013 | 1698 | 0.080 |
Why?
|
| Illinois | 2 | 2011 | 515 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2023 | 891 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2012 | 283 | 0.080 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 477 | 0.080 |
Why?
|
| Myosin Heavy Chains | 2 | 2020 | 86 | 0.080 |
Why?
|
| Echo-Planar Imaging | 1 | 2010 | 48 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2013 | 981 | 0.080 |
Why?
|
| Cerebral Arterial Diseases | 2 | 1995 | 7 | 0.080 |
Why?
|
| Receptors, TIE | 2 | 2001 | 2 | 0.080 |
Why?
|
| Receptor, TIE-1 | 2 | 2001 | 3 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 1990 | 64 | 0.080 |
Why?
|
| Spinal Puncture | 1 | 1990 | 37 | 0.080 |
Why?
|
| Receptor, TIE-2 | 2 | 2001 | 18 | 0.080 |
Why?
|
| Equipment Design | 3 | 2000 | 411 | 0.080 |
Why?
|
| Perfusion | 2 | 2021 | 260 | 0.080 |
Why?
|
| von Willebrand Factor | 2 | 2001 | 40 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 292 | 0.080 |
Why?
|
| Recurrence | 6 | 1996 | 1188 | 0.080 |
Why?
|
| RNA Splicing | 1 | 2011 | 157 | 0.080 |
Why?
|
| Glasgow Coma Scale | 2 | 2000 | 72 | 0.080 |
Why?
|
| Animals, Genetically Modified | 2 | 2021 | 186 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2019 | 1129 | 0.080 |
Why?
|
| Genetic Linkage | 5 | 2001 | 613 | 0.080 |
Why?
|
| Medical History Taking | 1 | 1990 | 80 | 0.080 |
Why?
|
| Genomics | 2 | 2021 | 848 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 875 | 0.070 |
Why?
|
| Antihypertensive Agents | 3 | 2024 | 256 | 0.070 |
Why?
|
| Patient Admission | 1 | 1990 | 118 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1171 | 0.070 |
Why?
|
| HLA-DR Antigens | 1 | 2009 | 56 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2009 | 46 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2025 | 1908 | 0.070 |
Why?
|
| Base Sequence | 3 | 2011 | 2207 | 0.070 |
Why?
|
| Ethers | 1 | 2008 | 13 | 0.070 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2008 | 42 | 0.070 |
Why?
|
| Polyurethanes | 1 | 2008 | 13 | 0.070 |
Why?
|
| Microdissection | 1 | 2008 | 17 | 0.070 |
Why?
|
| Weights and Measures | 1 | 2008 | 7 | 0.070 |
Why?
|
| Medical Illustration | 1 | 2008 | 14 | 0.070 |
Why?
|
| Brachial Plexus | 1 | 2008 | 5 | 0.070 |
Why?
|
| Umbilical Cord | 1 | 2008 | 39 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 89 | 0.070 |
Why?
|
| Magnetics | 1 | 2008 | 39 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 49 | 0.070 |
Why?
|
| Respiratory Paralysis | 1 | 2008 | 9 | 0.070 |
Why?
|
| Basilar Artery | 2 | 2005 | 39 | 0.070 |
Why?
|
| Thrombosis | 1 | 2011 | 308 | 0.070 |
Why?
|
| Collagen | 4 | 2005 | 301 | 0.070 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 120 | 0.070 |
Why?
|
| Meningioma | 1 | 1989 | 62 | 0.070 |
Why?
|
| Lasers | 1 | 2008 | 99 | 0.070 |
Why?
|
| Fluorocarbons | 1 | 2008 | 49 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2008 | 72 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2009 | 379 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 183 | 0.070 |
Why?
|
| Japan | 1 | 2008 | 299 | 0.070 |
Why?
|
| Spinal Cord Diseases | 2 | 2000 | 88 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2009 | 224 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2004 | 96 | 0.070 |
Why?
|
| Alcoholism | 1 | 1990 | 188 | 0.070 |
Why?
|
| Nerve Block | 1 | 2008 | 51 | 0.070 |
Why?
|
| United States | 8 | 2014 | 7581 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2025 | 373 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2018 | 23 | 0.070 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2005 | 19 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 121 | 0.070 |
Why?
|
| Postoperative Period | 5 | 1992 | 315 | 0.070 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 83 | 0.070 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 1999 | 30 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 247 | 0.070 |
Why?
|
| Smoking | 1 | 2011 | 647 | 0.070 |
Why?
|
| Regional Blood Flow | 3 | 1998 | 183 | 0.070 |
Why?
|
| Animals, Newborn | 2 | 2021 | 513 | 0.070 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 300 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2009 | 1518 | 0.060 |
Why?
|
| Gliosis | 4 | 2000 | 32 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2008 | 416 | 0.060 |
Why?
|
| Hemodilution | 1 | 1987 | 13 | 0.060 |
Why?
|
| Exons | 2 | 2007 | 447 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2007 | 206 | 0.060 |
Why?
|
| Patient Care Team | 2 | 2000 | 297 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 606 | 0.060 |
Why?
|
| Colorado | 1 | 2006 | 38 | 0.060 |
Why?
|
| Intestines | 2 | 2020 | 433 | 0.060 |
Why?
|
| Genes | 2 | 1998 | 256 | 0.060 |
Why?
|
| Arachnoid | 1 | 1986 | 4 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 2889 | 0.060 |
Why?
|
| Pia Mater | 1 | 1986 | 10 | 0.060 |
Why?
|
| Tissue Engineering | 1 | 2008 | 202 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2020 | 696 | 0.060 |
Why?
|
| Case Management | 1 | 2006 | 28 | 0.060 |
Why?
|
| Fibronectins | 2 | 2005 | 100 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 1986 | 44 | 0.060 |
Why?
|
| Microsurgery | 4 | 2005 | 100 | 0.060 |
Why?
|
| Inheritance Patterns | 1 | 2006 | 53 | 0.060 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2017 | 22 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2006 | 58 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2002 | 291 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2011 | 727 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 381 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2005 | 5 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 691 | 0.060 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2005 | 9 | 0.060 |
Why?
|
| Renal Artery Obstruction | 1 | 2005 | 16 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 709 | 0.060 |
Why?
|
| Cerebellar Diseases | 1 | 2005 | 22 | 0.060 |
Why?
|
| Vertebral Artery | 1 | 2005 | 28 | 0.050 |
Why?
|
| Radial Artery | 1 | 2005 | 37 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 66 | 0.050 |
Why?
|
| Family | 1 | 2006 | 319 | 0.050 |
Why?
|
| Dexamethasone | 2 | 2019 | 311 | 0.050 |
Why?
|
| Skull | 2 | 2020 | 267 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2021 | 657 | 0.050 |
Why?
|
| Epilepsy, Complex Partial | 2 | 1995 | 7 | 0.050 |
Why?
|
| Nocardia Infections | 1 | 1984 | 4 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1385 | 0.050 |
Why?
|
| Diagnostic Imaging | 4 | 2008 | 448 | 0.050 |
Why?
|
| Laminin | 1 | 2005 | 89 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2006 | 187 | 0.050 |
Why?
|
| Myosins | 1 | 2005 | 86 | 0.050 |
Why?
|
| Pregnancy | 1 | 2011 | 3128 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 1984 | 56 | 0.050 |
Why?
|
| Angiopoietins | 1 | 2004 | 6 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 302 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2024 | 42 | 0.050 |
Why?
|
| Blood Pressure | 2 | 1990 | 887 | 0.050 |
Why?
|
| Probability | 2 | 2023 | 352 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 65 | 0.050 |
Why?
|
| Movement Disorders | 2 | 2008 | 43 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 222 | 0.050 |
Why?
|
| Radiography | 4 | 2009 | 750 | 0.050 |
Why?
|
| Risk | 4 | 2003 | 651 | 0.050 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2004 | 86 | 0.050 |
Why?
|
| ROC Curve | 2 | 2018 | 774 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 191 | 0.050 |
Why?
|
| Indomethacin | 1 | 1983 | 58 | 0.050 |
Why?
|
| Length of Stay | 2 | 2012 | 820 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 366 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 147 | 0.050 |
Why?
|
| Registries | 2 | 2006 | 995 | 0.050 |
Why?
|
| Glasgow Outcome Scale | 1 | 2022 | 9 | 0.050 |
Why?
|
| Anxiety | 1 | 2025 | 336 | 0.050 |
Why?
|
| Integrin beta1 | 1 | 2022 | 34 | 0.050 |
Why?
|
| Migraine Disorders | 2 | 2020 | 41 | 0.050 |
Why?
|
| Biopsy | 2 | 2024 | 1172 | 0.050 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2003 | 48 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2006 | 564 | 0.050 |
Why?
|
| Spinal Stenosis | 1 | 2003 | 50 | 0.050 |
Why?
|
| Comorbidity | 3 | 2003 | 1003 | 0.050 |
Why?
|
| Sensation Disorders | 2 | 2008 | 30 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 79 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 281 | 0.050 |
Why?
|
| Carotid Artery Injuries | 1 | 1982 | 21 | 0.050 |
Why?
|
| Forecasting | 2 | 2002 | 288 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 1982 | 36 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 177 | 0.050 |
Why?
|
| Spondylolisthesis | 1 | 2003 | 68 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 221 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 1982 | 106 | 0.040 |
Why?
|
| Infusions, Intraventricular | 1 | 2021 | 5 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1055 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 55 | 0.040 |
Why?
|
| Headache | 3 | 2001 | 75 | 0.040 |
Why?
|
| Smooth Muscle Myosins | 1 | 2001 | 4 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2001 | 80 | 0.040 |
Why?
|
| Mesencephalon | 1 | 2002 | 67 | 0.040 |
Why?
|
| Alleles | 1 | 2005 | 1139 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 346 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1994 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 15 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 303 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2003 | 523 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2021 | 99 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 45 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2021 | 83 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2019 | 158 | 0.040 |
Why?
|
| Mosaicism | 1 | 2021 | 73 | 0.040 |
Why?
|
| Technetium Tc 99m Exametazime | 2 | 1998 | 5 | 0.040 |
Why?
|
| Cushing Syndrome | 1 | 2000 | 25 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 83 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 49 | 0.040 |
Why?
|
| ADAMTS4 Protein | 1 | 2020 | 4 | 0.040 |
Why?
|
| ADAMTS1 Protein | 1 | 2020 | 5 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2001 | 57 | 0.040 |
Why?
|
| Arteries | 2 | 2005 | 170 | 0.040 |
Why?
|
| RNA | 1 | 2005 | 574 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2000 | 30 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 177 | 0.040 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 145 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2020 | 32 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1987 | 1447 | 0.040 |
Why?
|
| Extracellular Space | 2 | 1994 | 82 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2021 | 132 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 2020 | 35 | 0.040 |
Why?
|
| Life Support Care | 1 | 2021 | 54 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 48 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 538 | 0.040 |
Why?
|
| Vimentin | 1 | 2020 | 47 | 0.040 |
Why?
|
| Spin Labels | 1 | 2020 | 105 | 0.040 |
Why?
|
| Constriction | 1 | 2000 | 26 | 0.040 |
Why?
|
| Electric Stimulation | 3 | 1999 | 341 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2000 | 88 | 0.040 |
Why?
|
| Tubulin | 1 | 2020 | 61 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 170 | 0.040 |
Why?
|
| Nevus of Ota | 1 | 1999 | 1 | 0.040 |
Why?
|
| Ligation | 1 | 2000 | 53 | 0.040 |
Why?
|
| Models, Biological | 3 | 2020 | 1768 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2021 | 121 | 0.040 |
Why?
|
| Proteolysis | 1 | 2020 | 124 | 0.040 |
Why?
|
| Eyelid Neoplasms | 1 | 1999 | 7 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 281 | 0.040 |
Why?
|
| Endothelium | 1 | 2020 | 59 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 106 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 1990 | 93 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 1982 | 217 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2001 | 219 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 70 | 0.040 |
Why?
|
| Endothelial Growth Factors | 2 | 1996 | 55 | 0.040 |
Why?
|
| Antibodies | 1 | 2001 | 346 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 105 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2003 | 355 | 0.040 |
Why?
|
| Models, Neurological | 2 | 2021 | 405 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 214 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 1526 | 0.040 |
Why?
|
| Databases, Bibliographic | 2 | 2009 | 17 | 0.040 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2020 | 58 | 0.040 |
Why?
|
| Metagenomics | 1 | 2020 | 101 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 324 | 0.040 |
Why?
|
| Cysts | 1 | 2000 | 99 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 21 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 232 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 260 | 0.040 |
Why?
|
| Founder Effect | 2 | 2011 | 106 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 75 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1980 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 1999 | 43 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2000 | 91 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 102 | 0.040 |
Why?
|
| Rupture, Spontaneous | 2 | 2006 | 42 | 0.040 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2018 | 4 | 0.040 |
Why?
|
| Epithelium | 1 | 2020 | 314 | 0.040 |
Why?
|
| Hypoxia | 1 | 2024 | 672 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 80 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 300 | 0.040 |
Why?
|
| Endoglin | 1 | 1998 | 20 | 0.040 |
Why?
|
| Auditory Cortex | 1 | 1999 | 63 | 0.040 |
Why?
|
| Skin | 2 | 1999 | 575 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 192 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 58 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1998 | 54 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2020 | 154 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 125 | 0.040 |
Why?
|
| Auditory Perception | 1 | 1999 | 104 | 0.030 |
Why?
|
| Reoperation | 2 | 1992 | 696 | 0.030 |
Why?
|
| Ligands | 1 | 2019 | 476 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2019 | 348 | 0.030 |
Why?
|
| Occludin | 1 | 2018 | 66 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2011 | 700 | 0.030 |
Why?
|
| Skull Base | 1 | 2018 | 50 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 360 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 2 | 1995 | 33 | 0.030 |
Why?
|
| Computer Communication Networks | 1 | 1998 | 24 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 480 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 88 | 0.030 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1997 | 14 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 341 | 0.030 |
Why?
|
| Haplotypes | 2 | 2011 | 647 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 162 | 0.030 |
Why?
|
| Homeostasis | 1 | 2020 | 459 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 209 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2017 | 37 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 201 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 212 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1998 | 90 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 2017 | 46 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2017 | 84 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2020 | 187 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 985 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 245 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 317 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 276 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 260 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 479 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2018 | 196 | 0.030 |
Why?
|
| Constriction, Pathologic | 3 | 1995 | 207 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2000 | 373 | 0.030 |
Why?
|
| Certification | 1 | 1997 | 58 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2017 | 235 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 379 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2016 | 11 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 1998 | 1051 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 355 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1359 | 0.030 |
Why?
|
| Decision Making | 2 | 2000 | 671 | 0.030 |
Why?
|
| Subtraction Technique | 2 | 1990 | 125 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1996 | 97 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1995 | 883 | 0.030 |
Why?
|
| Greece, Ancient | 1 | 1995 | 1 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2016 | 57 | 0.030 |
Why?
|
| Spinal Nerve Roots | 1 | 1995 | 20 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 1995 | 541 | 0.030 |
Why?
|
| Brain Injuries | 1 | 1998 | 139 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2019 | 700 | 0.030 |
Why?
|
| History, Ancient | 1 | 1995 | 80 | 0.030 |
Why?
|
| Spinal Injuries | 1 | 1995 | 28 | 0.030 |
Why?
|
| Melanoma | 1 | 1999 | 494 | 0.030 |
Why?
|
| Respiratory Insufficiency | 2 | 2008 | 199 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 116 | 0.030 |
Why?
|
| Curriculum | 1 | 2000 | 590 | 0.030 |
Why?
|
| Sex Factors | 2 | 1990 | 1102 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 1236 | 0.030 |
Why?
|
| Syringomyelia | 2 | 1991 | 14 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 621 | 0.030 |
Why?
|
| Glucose | 1 | 2017 | 686 | 0.030 |
Why?
|
| Barbiturates | 1 | 1994 | 12 | 0.030 |
Why?
|
| Sensation | 1 | 1994 | 48 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1994 | 21 | 0.030 |
Why?
|
| Arnold-Chiari Malformation | 2 | 1991 | 25 | 0.030 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1994 | 13 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 172 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 1994 | 67 | 0.030 |
Why?
|
| Causality | 1 | 1994 | 82 | 0.030 |
Why?
|
| Diffusion | 1 | 1994 | 94 | 0.030 |
Why?
|
| Organotechnetium Compounds | 1 | 1993 | 10 | 0.020 |
Why?
|
| Panic Disorder | 1 | 1993 | 21 | 0.020 |
Why?
|
| Oximes | 1 | 1993 | 18 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 1993 | 38 | 0.020 |
Why?
|
| Thromboxane A2 | 2 | 1983 | 11 | 0.020 |
Why?
|
| Dizziness | 1 | 1993 | 25 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 420 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 1993 | 104 | 0.020 |
Why?
|
| Risk Reduction Behavior | 2 | 2003 | 100 | 0.020 |
Why?
|
| Seasons | 1 | 1994 | 239 | 0.020 |
Why?
|
| Cats | 2 | 1983 | 281 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 2787 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1992 | 23 | 0.020 |
Why?
|
| Xenon Radioisotopes | 2 | 1982 | 9 | 0.020 |
Why?
|
| Mannitol | 1 | 1992 | 49 | 0.020 |
Why?
|
| Brain Stem Infarctions | 1 | 2012 | 5 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2012 | 12 | 0.020 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 19 | 0.020 |
Why?
|
| Psychosurgery | 1 | 1992 | 15 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 1992 | 60 | 0.020 |
Why?
|
| Subdural Space | 1 | 1992 | 17 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 181 | 0.020 |
Why?
|
| Cognition | 2 | 1999 | 625 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 833 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1660 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2011 | 19 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 205 | 0.020 |
Why?
|
| Respiration Disorders | 1 | 2011 | 42 | 0.020 |
Why?
|
| France | 1 | 2011 | 52 | 0.020 |
Why?
|
| Rats | 2 | 1995 | 4028 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 154 | 0.020 |
Why?
|
| Angiomatosis | 1 | 1990 | 4 | 0.020 |
Why?
|
| Spinal Neoplasms | 1 | 1992 | 124 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 1991 | 23 | 0.020 |
Why?
|
| Models, Genetic | 1 | 1996 | 970 | 0.020 |
Why?
|
| Encephalocele | 1 | 1990 | 23 | 0.020 |
Why?
|
| Breeding | 1 | 2010 | 42 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2000 | 1074 | 0.020 |
Why?
|
| Cerebral Infarction | 3 | 1991 | 71 | 0.020 |
Why?
|
| Edema, Cardiac | 1 | 2010 | 4 | 0.020 |
Why?
|
| Genome, Human | 1 | 1995 | 823 | 0.020 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 25 | 0.020 |
Why?
|
| Paraplegia | 1 | 1990 | 20 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1990 | 83 | 0.020 |
Why?
|
| Parietal Lobe | 1 | 1991 | 114 | 0.020 |
Why?
|
| Animal Structures | 1 | 2010 | 27 | 0.020 |
Why?
|
| England | 1 | 1990 | 38 | 0.020 |
Why?
|
| Leg | 1 | 1990 | 139 | 0.020 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1989 | 5 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2010 | 53 | 0.020 |
Why?
|
| Video Recording | 1 | 1991 | 210 | 0.020 |
Why?
|
| DNA | 1 | 1995 | 1260 | 0.020 |
Why?
|
| Dementia | 1 | 1991 | 213 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1989 | 37 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1989 | 109 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 241 | 0.020 |
Why?
|
| Hippocampus | 1 | 1992 | 451 | 0.020 |
Why?
|
| Consciousness Disorders | 1 | 2008 | 13 | 0.020 |
Why?
|
| Sturge-Weber Syndrome | 2 | 2001 | 9 | 0.020 |
Why?
|
| Phrenic Nerve | 1 | 2008 | 49 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 556 | 0.020 |
Why?
|
| Immune System | 1 | 2009 | 101 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 112 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 110 | 0.020 |
Why?
|
| Morphine | 1 | 2008 | 127 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 2008 | 98 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 1999 | 1519 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 827 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 528 | 0.020 |
Why?
|
| Psychology | 1 | 2006 | 26 | 0.010 |
Why?
|
| Random Allocation | 1 | 1986 | 308 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 274 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1986 | 573 | 0.010 |
Why?
|
| Brachiocephalic Trunk | 1 | 2005 | 14 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2005 | 47 | 0.010 |
Why?
|
| Aortography | 1 | 2005 | 57 | 0.010 |
Why?
|
| Vasospasm, Intracranial | 1 | 2005 | 36 | 0.010 |
Why?
|
| Nocardia asteroides | 1 | 1984 | 1 | 0.010 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2005 | 54 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 2005 | 90 | 0.010 |
Why?
|
| Sulfadiazine | 1 | 1984 | 23 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2007 | 438 | 0.010 |
Why?
|
| Debridement | 1 | 1984 | 59 | 0.010 |
Why?
|
| Laminectomy | 1 | 1984 | 61 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 515 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 116 | 0.010 |
Why?
|
| Pituitary Irradiation | 1 | 1982 | 3 | 0.010 |
Why?
|
| Acromegaly | 1 | 1982 | 5 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2003 | 89 | 0.010 |
Why?
|
| Bias | 1 | 2003 | 136 | 0.010 |
Why?
|
| Yttrium Radioisotopes | 1 | 1982 | 47 | 0.010 |
Why?
|
| Computers | 1 | 1982 | 102 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 389 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1982 | 180 | 0.010 |
Why?
|
| Evoked Potentials | 2 | 1993 | 193 | 0.010 |
Why?
|
| Netherlands | 1 | 2001 | 25 | 0.010 |
Why?
|
| Minnesota | 1 | 2001 | 49 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1999 | 2427 | 0.010 |
Why?
|
| Brachytherapy | 1 | 1982 | 128 | 0.010 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2001 | 29 | 0.010 |
Why?
|
| Hamartoma | 1 | 2001 | 33 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2001 | 64 | 0.010 |
Why?
|
| Sella Turcica | 1 | 2000 | 17 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2001 | 69 | 0.010 |
Why?
|
| Hemiplegia | 2 | 1991 | 11 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2001 | 174 | 0.010 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2000 | 50 | 0.010 |
Why?
|
| Myelography | 1 | 2000 | 10 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 206 | 0.010 |
Why?
|
| Hand | 1 | 2001 | 142 | 0.010 |
Why?
|
| Hemosiderin | 1 | 2000 | 2 | 0.010 |
Why?
|
| Syndrome | 1 | 2001 | 432 | 0.010 |
Why?
|
| Hernia | 1 | 2000 | 21 | 0.010 |
Why?
|
| Educational Status | 1 | 2001 | 195 | 0.010 |
Why?
|
| Intracranial Thrombosis | 1 | 2000 | 31 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2001 | 229 | 0.010 |
Why?
|
| Names | 1 | 1999 | 11 | 0.010 |
Why?
|
| Morphogenesis | 1 | 2001 | 204 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 429 | 0.010 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2001 | 142 | 0.010 |
Why?
|
| Spinal Fusion | 1 | 1984 | 347 | 0.010 |
Why?
|
| Verbal Behavior | 1 | 1999 | 33 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2001 | 202 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2001 | 192 | 0.010 |
Why?
|
| Speech | 1 | 1999 | 90 | 0.010 |
Why?
|
| Motor Activity | 1 | 2001 | 323 | 0.010 |
Why?
|
| Lod Score | 1 | 1998 | 152 | 0.010 |
Why?
|
| Calcinosis | 1 | 2000 | 219 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 196 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 494 | 0.010 |
Why?
|
| Ulcer | 1 | 1996 | 38 | 0.010 |
Why?
|
| Aneurysm, Infected | 1 | 1996 | 14 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1996 | 54 | 0.010 |
Why?
|
| Lymphokines | 1 | 1996 | 74 | 0.010 |
Why?
|
| Elastin | 1 | 1995 | 8 | 0.010 |
Why?
|
| Mass Screening | 1 | 2000 | 706 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 1995 | 18 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 156 | 0.010 |
Why?
|
| Time | 1 | 1995 | 80 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 37 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1995 | 57 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1996 | 250 | 0.010 |
Why?
|
| Hemangioma, Capillary | 1 | 1993 | 8 | 0.010 |
Why?
|
| Capillaries | 1 | 1993 | 83 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1993 | 49 | 0.010 |
Why?
|
| Sclerosis | 1 | 1992 | 31 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1993 | 145 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1991 | 17 | 0.010 |
Why?
|
| Life Tables | 1 | 1991 | 46 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1995 | 798 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1992 | 404 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 941 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 177 | 0.000 |
Why?
|
| Synapses | 1 | 1992 | 273 | 0.000 |
Why?
|
| Aphasia | 1 | 1989 | 16 | 0.000 |
Why?
|
| Spinal Cord Injuries | 1 | 1991 | 109 | 0.000 |
Why?
|
| Remission Induction | 1 | 1991 | 737 | 0.000 |
Why?
|
| Action Potentials | 1 | 1992 | 575 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1991 | 679 | 0.000 |
Why?
|
| Neurons | 1 | 1992 | 1567 | 0.000 |
Why?
|